Literature DB >> 23238889

Differential effects of exogenous and autocrine growth hormone on LNCaP prostate cancer cell proliferation and survival.

Alona O Nakonechnaya1, Holly S Jefferson, Xiaofei Chen, Brian M Shewchuk.   

Abstract

The prostate gland is regulated by multiple hormones and growth factors that may also affect prostate tumorigenesis. Growth hormone (GH) contributes to prostate development and function, but the direct effects of GH on prostate cancer cells are not well understood. The expression of endogenous GH in prostate cancer cell lines has also been observed, suggesting the potential for an effect of autocrine GH. In the present study, we measure the levels of GH and GH receptor (GHR) mRNA in multiple prostate cancer and normal prostate-derived cell lines, and compare the effects of exogenous and autocrine GH on LNCaP prostate cancer cell proliferation and apoptosis, and the associated signal transduction pathways. We found that GHR and GH expression were higher in the prostate cancer cell lines, and that exogenous GH increased LNCaP cell proliferation, but had no effect on apoptosis. In contrast, autocrine GH overexpression reduced LNCaP cell proliferation and increased apoptosis. The distinct actions of exogenous and autocrine GH were accompanied by differences in the involvement of GHR-associated signal transduction pathways, and were paralleled by an alteration in the subcellular localization of GHR, in which autocrine GH appeared to sequester GHR in the Golgi and endoplasmic reticulum. This alteration of GHR trafficking may underlie a distinct mode of GH-mediated signaling associated with the effect of autocrine GH. These findings clarify the potential effects of GH on prostate cancer cell function, and indicate that the activity of autocrine GH may be distinct from that of endocrine GH in prostate cancer cells.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23238889     DOI: 10.1002/jcb.24473

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

1.  Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells.

Authors:  M Victoria Recouvreux; J Boyang Wu; Allen C Gao; Svetlana Zonis; Vera Chesnokova; Neil Bhowmick; Leland W Chung; Shlomo Melmed
Journal:  Endocrinology       Date:  2017-07-01       Impact factor: 4.736

2.  GH Action in Prostate Cancer Cells Promotes Proliferation, Limits Apoptosis, and Regulates Cancer-related Gene Expression.

Authors:  Christopher J Unterberger; Vilena I Maklakova; Michelle Lazar; Paige D Arneson; Sean J Mcilwain; Philippos K Tsourkas; Rong Hu; John J Kopchick; Steven M Swanson; Paul C Marker
Journal:  Endocrinology       Date:  2022-05-01       Impact factor: 4.736

3.  Exogenous growth hormone promotes an epithelial-mesenchymal hybrid phenotype in cancerous HeLa cells but not in non-cancerous HEK293 cells.

Authors:  E M Olascoaga-Caso; E Tamariz-Domínguez; J C Rodríguez-Alba; E Juárez-Aguilar
Journal:  Mol Cell Biochem       Date:  2022-10-12       Impact factor: 3.842

4.  Growth hormone is a cellular senescence target in pituitary and nonpituitary cells.

Authors:  Vera Chesnokova; Cuiqi Zhou; Anat Ben-Shlomo; Svetlana Zonis; Yuji Tani; Song-Guang Ren; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-12       Impact factor: 11.205

Review 5.  Growth hormone and reproduction: a review of endocrine and autocrine/paracrine interactions.

Authors:  Kerry L Hull; Steve Harvey
Journal:  Int J Endocrinol       Date:  2014-12-15       Impact factor: 3.257

Review 6.  Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?

Authors:  Paul Beinhoff; Lavannya Sabharwal; Vindhya Udhane; Cristina Maranto; Peter S LaViolette; Kenneth M Jacobsohn; Susan Tsai; Kenneth A Iczkowski; Liang Wang; William A Hall; Scott M Dehm; Deepak Kilari; Marja T Nevalainen
Journal:  Cancers (Basel)       Date:  2021-10-17       Impact factor: 6.575

Review 7.  Why Should Growth Hormone (GH) Be Considered a Promising Therapeutic Agent for Arteriogenesis? Insights from the GHAS Trial.

Authors:  Diego Caicedo; Pablo Devesa; Clara V Alvarez; Jesús Devesa
Journal:  Cells       Date:  2020-03-27       Impact factor: 6.600

8.  SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.

Authors:  Julia Hoefer; Johann Kern; Philipp Ofer; Iris E Eder; Georg Schäfer; Dimo Dietrich; Glen Kristiansen; Stephan Geley; Johannes Rainer; Eberhard Gunsilius; Helmut Klocker; Zoran Culig; Martin Puhr
Journal:  Endocr Relat Cancer       Date:  2014-01-30       Impact factor: 5.678

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.